Abstract:Human and murine brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions, and specific miRNA abundances are significantly and progressively altered in neurological disorders such as Alzheimer disease (AD), prion disease (PrD) and transgenic AD (Tg-AD) murine models when compared to age-matched controls. The innate-immune and pro-inflammatory, NF-kB-regulated 22-nucleotide single-stranded miRNA-146a is significantly up-regulated in parallel with the development of AD and PrD and with the onset of amyloidogenesis in several Tg-AD murine models. Here for the first time we provide evidence of significant up-regulation of miRNA-146a in amyloid-and-cytokine-stressed human neuronal-glial cells in primary co-culture and in the brains of 5xFAD mice [Tg(APPSwFlLon,PSEN1*M146L *L286V)6799Vas] which bear 5 (APP695+PSEN1) mutations that strongly drive the generation of Aβ42 peptides. AAV-miRNA vectors, microRNA analysis, 5xFAD Tg-AD models, RNA sequencing, RT-PCR, LED-Northern, microfluidic and bioinformatics technologies. Using stereotactic bilateral hippocampal injection of a scrambled AAV-miRNA-146a vector into 5xFAD brains as a baseline, selective AAV-miRNA-146a sponging vectors delivered into the hippocampus of 5xFAD mice exhibited (i) decreases in host miRNA-146a expression; (ii) increases in expression of the complement control glycoprotein complement factor H (CFH); (iii) decreases in BACE1, sAPPβsw and the generation of Aβ42 peptides; (iv) decreases in the expression of inflammatory and microglial markers including cyclooxygenase-2 (COX-2), glial fibrillary acidic protein (GFAP) and Iba1; (v) increased expression of the synaptic markers SYN1 and NR2B; and (vi) a significant improvement in cognitive performance in maze tests (NOR and Y-maze). Collectively, the results suggest that the implementation of a novel therapeutic strategy involving the sponging of miRNA-146a and related pro-inflammatory, pathogenic miRNAs may be useful in the effective treatment of AD and other progressive, age-related neurological disorders. Support: Research on miRNA in the Lukiw laboratory involving the innate-immune response in AD, AMD and in other forms of neurological or retinal disease, amyloidogenesis and neuro-inflammation was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and grants from the NIH NEI and NIA.

MiR-137-3p Mechanisms of Action and Blood-Brain Barrier Penetrating and Neuron-Targeting Lipid Nanoparticles Deliver Mir-137-3p for the Treatment of Alzheimer's Disease

MicroRNA-139 Modulates Alzheimer's-associated Pathogenesis in SAMP8 Mice by Targeting Cannabinoid Receptor Type 2.

Brain‐Penetration and Neuron‐Targeting DNA Nanoflowers Co‐Delivering miR‐124 and Rutin for Synergistic Therapy of Alzheimer's Disease

Intranasal Delivery of Targeted Nanoparticles Loaded with Mir-132 to Brain for the Treatment of Neurodegenerative Diseases.

MicroRNA-195 liposomes for therapy of Alzheimer's disease

MicroRNA Mir-103A-3p Targets NPAS3 to Regulate Progression of Alzheimer’s Disease

Human microRNA-153-3p targets specific neuronal genes and is associated with the risk of Alzheimer's disease.

Sponging of mirna-146a using aav-anti-mirna-146a-vectors mediates synaptic and amyloidogenic neuropathology and cognitive deficits in a 5xfad murine model of alzheimer’s disease

miRNA375-3p/rapamycin mediates the mTOR pathway by decreasing PS1, enhances microglial cell activity to regulate autophagy in Alzheimer's disease

Intrahippocampal Mir-342-3p Inhibition Reduces Β-Amyloid Plaques and Ameliorates Learning and Memory in Alzheimer's Disease.

miR-429-3p mediates memory decline by targeting MKP-1 to reduce surface GluA1-containing AMPA receptors in a mouse model of Alzheimer's disease

LncRNA RMRP accelerates autophagy-mediated neurons apoptosis through miR-3142/TRIB3 signaling axis in alzheimer's disease

Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer’s Disease Therapy

Elevated Levels of miR-144-3p Induce Cholinergic Degeneration by Impairing the Maturation of NGF in Alzheimer’s Disease

O3‐01‐05: MIR‐204 ATTENUATES MEMORY DEFICITS IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

miR-200a-3p promotes b-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer's disease

MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer’s disease

MicroRNAs: Pioneering Regulators in Alzheimer’s Disease Pathogenesis, Diagnosis, and Therapy

Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease

A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease

Unveiling the Role of Novel miRNA PC-5P-12969 in Alleviating Alzheimer's Disease